CAGRI – GLP-1S 5mg/5mg

Cagri-GLP S 5mg / 5mg

Dual peptide research blend studied for amylin receptor activity, GLP pathway signaling, and metabolic regulation models.

Compound Overview

Cagri-GLP S is a dual research formulation combining Cagrilintide, a long-acting amylin analogue, with GLP S, a GLP-based peptide studied for incretin-related signaling and metabolic pathway activity. This type of combination is evaluated in laboratory settings for its potential interaction across complementary endocrine and appetite-regulation pathways.

In controlled research models, Cagrilintide is commonly examined for amylin receptor-mediated effects involving satiety signaling, gastric modulation, and postprandial metabolic regulation. GLP-based peptides are frequently studied for receptor activity associated with glucose-dependent signaling, digestive pathway response, and broader metabolic system research. Combined formulations are often included in experimental designs focused on multi-pathway peptide activity.

Product Specifications

• Product Name: Cagri-GLP S Blend
• Cagrilintide Content: 5mg
• GLP S Content: 5mg
• Total Peptide Content: 10mg per vial
• Form: Lyophilized peptide powder blend
• Intended Use: Research use only